Resistance to antiretroviral therapy;Resistencias al tratamiento antirretroviral

Farmacia Hospitalaria

Volumn 28, Issue 6 SUPPL. 1, 2004, Pages 55-71

  Alberdi Leniz, Aintzane ^a   Tuset Creus, M ^a   Martin Conde M ^a   Del Cacho Del Cacho, E ^a   Nigorra Caro, M ^a   Codina Jane C ^a   Ribas I Sala, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiretroviral therapy; Genotypical test; HAART; HIV; Phenotypical test; Resistance to treatment

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CAPRAVIRINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DNA; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; REVIEW; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS;

EID: 14644412959     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progresión and virológic failure on highly active antirretroviral therapy in HIV-1 patients: a prospective cohort sutdy. Lancet 1999; 353: 863-8.
2. Scott WA. The enzymatic basis for thymidine analogue resistance in HIV-1. AIDS Reviews 2001; 3: 194-200.
3. Gotte M, Arion D, Parniak Ma and Wainberg Ma. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated dna synthesis. J Virol 2000; 74: 3579-85.
4. Margot N, Isaccson E, McGowan I, Cheng A, Schooley R, Miller MD. Genotypic and phenotypye analyses of HIV-I in antiretroviral-experienced patients treated with Tenofovir DF. AIDS 2002; 16 (9): 1227-35.
5. Joly V, Moroni M, Concia E, Lazzarin A, Hirschel B, Jost J, et al. Delavirdine in combination with zidovudine in treatment of HIV-1 infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. Antimicrob Agents Chemother 2000; 44: 3155-7.
6. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary path-ways of HIV-1 resistance to protease inhibitors. virus fitness in the absence and in the presence of drug. J Virol 2000; 74: 8524-31.
7. Barreiro P, Camino N, De Mendoza C, Valer L, Núñez M, Martín-Carbonero L, et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Inter J Antimicrob Agents 2002; 20: 438-43.
8. th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003. Abstract 141.
9. Miralles G, Lalezari J, Bellos N, Richmond G, Zhang Y, Murchison H, et al. T-1249 demostrates potent antiviral activity over 10-day dosing in most patients who have failed a regimen containing enfuvirtide: planned interim analysis of T 1249-102, a phase I/II study. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003. Abstract 14LB.
10. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Con Clin Trials 1996; 17: 1-12.
11. Whiting P, Rutjes A, Reitsma JB, Bossuyt PMM and Kleijnen J. The development of QUADAS: a tool for the quality assesment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology 2003; 3: 1-13.
12. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Topics In HIV Medicine 2002; 10: 21-5.
13. Soriano V, Miró JM, Guerrero A. Primary resistance to antiretroviral agents. Enferm Infecc Microbiol Clin 2001; 19 (Monográfico): 22-5.
14. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9.
15. Wensing AM, Van De Vijver D, Asjo B. Analysis from more than 1600 newly diagnosed patients with HIV from 17 european countries shows that 10% of the patients carry primary drug-resistance: The Catch Study. 2nd International AIDS Society Conference on HIV pathogenesis and treatment; Paris July 13-16, 2003; Abstract lb1.
16. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor. Hipersusceptibility: a prospective cohort analysis. AIDS 2002; 16: 33-40.
17. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-28.
18. Deeks S. Nonnucleoside Reverse Transcriptase Inhibitors. J Acquir Immune Defic Syndr 2001; 26 (Supl.): 25-33.
19. Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT, A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hipersensitivity to amprenavir. J Virol 2000; 74: 4414-9.
20. Zachary KC, Hanna Gj, Dáquila Rt. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin Infect Dis 2001; 33: 2075-7.
21. Obry V, Race E, Vray M, Meynard JL, Monrad-Joubett L, Descamps D, et al. Hypersusceptibility to protease inhibitors associated with mutated proteases at codons 30 and 88 in treated patients. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle) 2002. Abstract 557-T.
22. Sommadossi J. Comparison of metabolism and in vitro antiviral Activity of stavudine versus other 2′, 3′-dideoxynucleoside analogues. J Infect Dis 1995; 171 (Supl. 2): 88-92.
23. Becher F, Pruvost AG, Schlemmer DD, Creminon CA, Goujard CM, Delfraissy JF, et al. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients. AIDS 2003; 17: 555-61.
24. Friedland Gh, Williams A. Attaining higher goals in HIV treatment: The central importance of adherence. AIDS 1999; 13 (Supl . 1): S61-72.
25. Cox SW, Aperia K, Albert J, Wahren B. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994; 10: 1725-9.
26. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanism of drug inhibition and resistance. J Mol Biol 1994; 243: 369-87.
27. Rodes B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, et al. Emergence of drug resistance mutations in HIV-2-infected subjetcs undergoing antirretroviral therapy. J Clin Microbiol 2000; 38: 1370-4.
28. Yang G, Song Q, Charles M, Drosopoulos WC, Arnold E, Prasad VR. Use of chimeric HIV types 1 and 2 reverses transcriptases for structure-function analisis and for maping susceptibility to non-nucleoside inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 326-33.
29. Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa A. Current Management Challenges In HIV: Antiretroviral Resistance. AIDS Read 2003; 13: 133-42.
30. Kuritzkes DR. Satellite Symposium At The 2nd las Conference On Pathogénesis And Treatment. Paris, July 13-16. 2003.
31. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000; 283: 2417-26.
32. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-9.
33. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-76.
34. Hackett J. Natural polymorphisms associated with resistance to protease inhibitors in non-subtype B HIV-1 Strains. 2nd International AIDS Society Conference on HIV pathogenesis and treatment; Paris 2003. Abstract 814.
35. th Conference on retroviruses and opportunistuc infections (Seattle). 2002. Abstract 46.
36. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non- nucleoside reverse transcriptase inhibitors. AIDS 2003; 17: F1-5.
37. st International AIDS Society Conference On HIV Pathogenesis And Treatment. (Buenos Aires) 2001. Abstract 124.
38. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, et al. Drug susceptibility in hiv infection after viral rebound in patients receiving indinavir-containing regimen. JAMA 2000; 283: 229-34.
39. th Conference On Retroviruses And Opportunistic Infections, (San Francisco) 2000. Abstract 238.
40. th Conference On Retroviruses And Opportunistuc Infections. February 8-11 (San Francisco 2004) Oral Abstract 52.
41. st Interscience Conference On Antimicrobial Agents And Chemotherapy; December 16-19, 2001; Chicago. Abstract 1768.
42. Pecora-Fulco P, Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003; 37: 1325-8.
43. Mayers DI. Drug-Resistant HIV-1: The virus strikes back. JAMA 1998; 279: 2000-2.
44. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-Usa Panel. JAMA 1998; 279: 1984-91.
45. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV. HIV 1 protease inhibitor are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37 (11): 3594-601.
46. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on haart in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002; 30 (3): 278-87.
47. nd International AIDS Society Conference On HIV Pathogenesis And Treatment; July 13-16, 2003; Paris, France. Abstract 833.
48. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37 (8): 1112-8.
49. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002; 16 (Supl. 1): S5-37.
50. Kemp Sd, Shi C, Bloor S, Harrigan Pr, Mellors Jw Larder BA. A Novel Polymorphism At Codon 333 Of HIV-1 Rt Can Facilitate Dual Resistance To Zidovudine And Lamivudine. J Virol 1998; 72: 5093-8.
51. Gallego O, Corral A, de Mendoza C, Rodes B, Soriano V. Prevalence of G333D/E in naive and pretreated patients. AIDS Res Hum Retroviruses 2002; 18: 857-60.
52. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci Usa 2002; 99: 16249-54.
53. Solomon A, Gorry P, Wightman F, Crowe SM. Use of CXCR4 and alternative co-receptors by HIV is strongly associated with immunological failure in individuals infected with drug-resistant virus. In Program And Abstracts Of The 11th Conference On Retroviruses And Opportunistic Infections. February 8-11 (San Francisco 2004). Abstract 654.
54. Wilson JW, Bean P. A Physician's Primer To Antiretroviral Drug Resistance Testing. AIDS Read 2000; 10: 469-78.
55. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic Drug Resitance Testing To Monitor Antiretroviral Chemotherapy. Clin Infect Dis 2001; 32: 774-82.
56. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patientes treated with antirretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-76.
57. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRA-DAPT randomised controlled trial. Lancet 1999; 353: 2195-9.
58. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: 83-93.
59. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-88.
60. Haubrich R, Keiser P, Lie YS, Leedom J, Richman D, McCutchan JA, et al. CCTG 575: A Randomized, Prospective Study Of Phenotype Testing Versus Standard Of Care For Patients Failing Antiretroviral Therapy [Abstract 80]. Antivir Ther 2001; 6 (Supl. 1): 63-71.
61. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure. AIDS 2002; 16: 727-36.
62. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring hiv drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (Argenta). AIDS 2002; 16: 369-79.
63. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-18.
64. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type Iinfected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38: 723-30.
65. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antirretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recomendations of an international AIDS Society-Usa Panel. Clin Infect Dis 2003; 37: 113-28.
66. Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, et al. Actualización de las recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el Virus de la Inmunodeficiencia Humana. http://www.gesidaseimc.com Marzo de 2004.
67. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring as a tool in HIV infection: current status and future directions. AIDS 2002; 16 (Supl. 1): S5-S37.
68. Meyer P, Matsuura S, Mian A, So A, Scottw. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Moll Cell 1999; 4: 35-43.
69. Loveday C. Nucleoside Reverse Transcriptase Inhibitor Resistance. J AIDS 2001; 26 (Supl.): 10-24.
70. Nijhuis M, Schuurman R, De Jong D, Van Leeuwen R, Lange J, Dannet S, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become coresistant to zidovudine in vivo. J Infect Dis 1997; 176: 398-405.
71. Kuritzkes DR, Shugarts D, Bakhtiari M, Poticha D, Johnson J, Rubin M, et al. Emergence of dual resistance to zidovudine and lamivudine in HIV-1 infected patients treated with zidovudine plus lamivudine as initial therapy. J Acquit Immune Defic Syndr 2000; 23: 26-34.
72. Kuritzkes D, Marschner I, Jonson V, Basset R, Eron JJ, Fischl, et al. Lamivudine in combination with zidovudine, stavudine or didanosine in patients with HIV-1 infection, a randomized, double-blind, placebo-cotrolled trial (Actg 306). AIDS 1999; 13: 685-94.
73. Miller MD, Antón K, Mulato A, Lamy PD, Cherrington JM. HIV-1 Expressing the lamivudine-associated M184V mutation in RT shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179: 92-100.
74. Whitcomb J, Paxinos E, Huang W, Marauta M, Limoli K Chappey C, et al. The presence of NAMs is highly correlated with reduced susceptibility to all ITIAN. 9th Conference On Retroviruses And Opportunistic Infections (Seattle) 2002 [Abstract 569].
75. Larder B, Bloor S. Analysis Of Clinical Isolates And Site-Directed Mutants Reveals The Genetic Determinants Of Didanosine Resistance. Antivir Ther 2001; 6 (Supl. 1): 38-9.
76. Casado J, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arno A, et al. ITINN resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000; 14: F1-7.
77. Deeks S. Nonnucleoside Reverse Transcriptase Inhibitors. J AIDS 2001; 26 (Supl.): 25-33.
78. Gulnik S, Suvorov L, Liu B, Yu B, Anderson B, Mituya H, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995; 34. 9282-7.
79. Mahalingam B, Louis JM, Reed CC, Adomat JM, Krouse J, Wang YF, et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem 1999; 263: 238-45.
80. Chen Z, Li Y, Schock H, Dawn H, Chen E, Kuo LC. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 1995; 270: 21433-6.
81. Nijhuis M, Schuurman R, De Jong D, Erickson J, Gustchina E, Albert J, et al. Increased fitness of drug resistant hiv-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349-59.
82. Kempf D, Isaacson J, King M, Brun SC, Yi Xu, Real K, et al. Identification of genotypic changes in hiv protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-9.
83. Beck I, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E, et al. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in HIV-1 associated with high level resistance to protease inhibitors. J Clin Microbiol 2002; 40: 1413-9.
84. International AIDS Society-USA Resistance mutations Project Panel. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10: 21-5.
85. Poveda E, Rodes B, Toro C, Martín-Carbonero L, González-Lahoz J, Soriano V. Evolution of gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002; 16: 1959-61.
86. Product Information: Emtriva (TM), emtricitabine capsules. Gilead Sciences, Inc. Foster City, CA, 07/2003. http://www.emtriva.com.
87. th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 323.
88. Vingerhoets S, De Baere I, Azijn H, Van den Bulcke T, Mckenna P, Pattery T, et al. Antiviral activity of TMC 125 against a panel of site-directed mutants encompassing mutations in vitro and in vivo. 11th Conference On Retroviruses And Opportunistic Infections. February 8-11 (San Francisco 2004) Abstract 621.
89. th Conference On Retroviruses And Opportunistic Infections. February 8-11 (San Francisco 2004) Abstract 625.
90. Murphy R, Pokrovsky V, Rozenbaum W, Wood R, Percival L, Odeshoo L, et al. Long-term efficacy and safety of atazanavir (ATV) with stavudine (d4T) and lamivudine (3TC) in patients previously treated with nelfinavir (NFV) or ATV: 108-week results of BMS study 008/044. 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 555.
91. Squires k, Mccallister S, Lazzarin A, Kumar P, De Jesús E, Nadler J, et al. Tipranavir/ritonavir (TPV/r) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: correlation of baseline genotype and antiviral activity in bi 1182.52. The 2nd IAS Conference on HIV Patogénesis and Treatment. July 13-17, 2003 Paris [Abstract 812].
92. De Meyer S, Van Marck H, Van De Bulcke T, Vingerhoets J, Azin H, Pauwels R, et al. Phenotypic and genotypic profiling of TMC 114 a potent next-generation PI, against some 1600 recent PI-resistant clinical isolates. 11th Conference On Retroviruses And Opportunistic Infections. February 8-11 (San Francisco 2004) Abstract 620.
93. th International HIV Drug Resistance Workshop, June 10-14. 2003. Cabo San Lucas. Mexico. Abstract 553.